Indix Combi (Indapamide, Perindopril Tosilate)

Indapamide increases urine output by inhibiting sodium‑chloride reabsorption in the kidney’s distal tubule, reducing fluid volume. Perindopril blocks the conversion of angiotensin I to angiotensin II, decreasing vasoconstriction and aldosterone release. Together they lower vascular resistance and blood volume, resulting in blood‑pressure reduction.

The specific dose of Indix Combi is determined by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health status. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety of Indix Combi in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Indix Combi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapy, the Indapamide‑Perindopril combination offers complementary mechanisms that can achieve better blood‑pressure control with potentially lower individual drug doses. It may be preferred over separate tablets for convenience, but clinicians consider patient‑specific factors such as renal function and electrolyte balance when selecting therapy.

Indix Combi tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required.

Indix Combi is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water. Do not crush or chew the tablet unless specifically instructed.

Serious risks include angioedema, severe hypotension, acute renal failure, and hyperkalemia. Patients should seek immediate medical attention if they experience swelling of the face or throat, fainting, sudden loss of kidney function, or signs of high potassium such as muscle weakness or irregular heartbeat.

Indix Combi is contraindicated in patients with known hypersensitivity to indapamide, perindopril, or any component of the formulation, as well as those with a history of angioedema related to ACE‑inhibitor therapy. It should also be avoided in individuals with severe renal impairment or hyperkalemia unless closely monitored.